NASDAQ · Biotechnology

ADMA Biologics Inc (ADMA) Stock

$10.68 -0.47% NASDAQ: ADMA Healthcare

Valuation

MetricValue
Price$10.68
Market Cap$2.39B
P/E Ratio14.08
P/B Ratio5.67
P/S Ratio4.59
EPS (TTM)$0.60
52-Week High$20.46
52-Week Low$7.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE39.59%
ROA24.69%
ROCE35.58%
Gross Margin61.27%
Operating Margin40.57%
Net Margin32.98%
Debt/Equity0.50
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$81.0M$154.0M$258.0M$426.0M$510.0M
Operating Profit$-58.0M$-39.0M$22.0M$139.0M$191.0M
Net Profit$-72.0M$-66.0M$-28.0M$198.0M$147.0M
EPS$-0.61$-0.43$-0.13$0.81$0.60
Op Margin-72.1%-25.6%8.4%32.6%37.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$276.0M$348.0M$329.0M$489.0M$624.0M
Total Liabilities$135.0M$196.0M$194.0M$140.0M$147.0M
Cash$51.0M$87.0M$51.0M$103.0M$88.0M
Borrowings$103.0M$154.0M$141.0M$82.0M$80.0M

Latest News

ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Simply Wall St. · Jul 15, 2026 ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run Simply Wall St. · Jul 15, 2026 ADMA: Lowering target price to $8.00 Argus Research · Jul 15, 2026 Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Zacks · Jul 13, 2026 Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? Zacks · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-112.0M$-60.0M$9.0M$119.0M$50.0M
Investing Cash Flow$-27.0M$-28.0M$-10.0M$-17.0M$-44.0M
Financing Cash Flow$0$-8.0M$-15.0M$-6.0M$-44.0M
Net Cash Flow$-5.0M$35.0M$-35.0M$52.0M$-16.0M
Free Cash Flow$-126.0M$-73.0M$4.0M$110.0M$28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.82
EV / EBITDA10.29
FCF Yield4.96%
Quick Ratio3.81
Interest Coverage24.53
Return 1Y-52.03%
Return 3Y121.18%
Return 5Y412.42%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUSArbutus Biopharma Corporation $4.22 -1.63% 5.63 $836.01M 0.00%
GRFSGrifols, S.A. $7.27 -0.27% 14.60 $6.15B 1.24%
IVVDInvivyd, Inc. $0.62 -7.51% -2.08 $182.34M 0.00%

About ADMA Biologics Inc

ADMA Biologics Inc (ADMA) stock trades at $10.68 with a market capitalization of $2.39B. The stock is valued at a price-to-earnings (P/E) ratio of 14.08, price-to-book of 5.67, price-to-sales of 4.59. Over the past 52 weeks the stock has ranged between $7.21 and $20.46, and currently trades 47.8% below its 52-week high.

On profitability, ADMA Biologics Inc generates a return on equity (ROE) of 39.59%, above the typical market range of roughly 12-15%, return on capital employed of 35.58%, an operating margin of 40.57%, a net profit margin of 32.98%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.